| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
REVIEW |
Department of Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
Correspondence to:
Correspondence to:
R J Siegert
Rehabilitation Teaching and Research Unit, Department of Medicine, Wellington School of Medicine, University of Otago, PO Box 7343, Wellington South, New Zealand; rsiegert{at}wnmeds.ac.nz
Several studies have reported high rates of depression in multiple sclerosis (MS) with a lifetime prevalence of 
50% and an annual prevalence of 20% not uncommon. Concern about the potential of new drug treatments to exacerbate or precipitate depression in MS has led to increased interest in the relation between MS and depression. This review on MS and depression identifies the following key issues: How common is depression in people with MS? Is depression in MS associated with lesions in specific regions of the central nervous system? Is there an increased risk of suicide in MS? Is there a higher than expected incidence of anxiety disorders in MS? Are fatigue and depressed mood related in MS? Is there a relation between depression and cognitive impairment in MS? Which psychosocial variables affect the development of depression in MS? Does treatment with interferon increase the risk of depression? How effective are treatments for MS patients with depression? Each of these issues is briefly reviewed with critical commentary, and some priorities for future research are suggested.
Abbreviations: BDI, Beck Depression Inventory; CBT, cognitive behavioural therapy; CES-D, Centre for Epidemiological Studies’ Depression Scale; MS, multiple sclerosis; SSRI, selective serotonin reuptake inhibitor
Keywords: multiple sclerosis; depression
This article has been cited by other articles:
|
|
 |
|
  P Nilsson, I Rorsman, E. Larsson, B Norrving, and M Sandberg-Wollheim Cognitive dysfunction 24-31 years after isolated optic neuritis Multiple Sclerosis, August 1, 2008; 14(7): 913 - 918. [Abstract] [PDF]
|
|
|
|
|
|
K Wynia, B Middel, J. van Dijk, J. De Keyser, and S. Reijneveld The impact of disabilities on quality of life in people with multiple sclerosis Multiple Sclerosis, August 1, 2008; 14(7): 972 - 980. [Abstract] [PDF]
|
|
|
|
|
|
M Koch, M Uyttenboogaart, A van Harten, M Heerings, and J De Keyser Fatigue, depression and progression in multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 815 - 822. [Abstract] [PDF]
|
|
|
|
 |
|
 M. P. Amato, B. Goretti, A. Ghezzi, S. Lori, V. Zipoli, E. Portaccio, L. Moiola, M. Falautano, M. F. De Caro, M. Lopez, et al. Cognitive and psychosocial features of childhood and juvenile MS Neurology, May 13, 2008; 70(20): 1891 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Goverover, H. Genova, F. Hillary, and J. DeLuca The relationship between neuropsychological measures and the Timed Instrumental Activities of Daily Living task in multiple sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 636 - 644. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Vahter, M. Kreegipuu, T. Talvik, and K. Gross-Paju One question as a screening instrument for depression in people with multiple sclerosis Clinical Rehabilitation, May 1, 2007; 21(5): 460 - 464. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Schilling, C. Brueckner-Totonji, V. Arolt, and B. T. Baune A Case of Multiple Sclerosis Masked by Depression and Diabetic Neuropathy Psychosomatics, August 1, 2006; 47(4): 361 - 363. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dilley and S. Fleminger Advances in neuropsychiatry: clinical implications Advan. Psychiatr. Treat., January 1, 2006; 12(1): 23 - 34. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
